CA3063140A1 - Biodegradable microparticles for sustained delivery of anti-angiogenic peptide - Google Patents

Biodegradable microparticles for sustained delivery of anti-angiogenic peptide Download PDF

Info

Publication number
CA3063140A1
CA3063140A1 CA3063140A CA3063140A CA3063140A1 CA 3063140 A1 CA3063140 A1 CA 3063140A1 CA 3063140 A CA3063140 A CA 3063140A CA 3063140 A CA3063140 A CA 3063140A CA 3063140 A1 CA3063140 A1 CA 3063140A1
Authority
CA
Canada
Prior art keywords
microparticle
seq
peptide
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3063140A
Other languages
English (en)
French (fr)
Inventor
Jordan J. Green
Niranjan Pandey
Aleksander S. Popel
Peter A. Campochiaro
Jayoung Kim
Raquel LIMA E. SILVA
Ron SHMUELI
Adam MIRANDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Asclepix Therapeutics Inc
Original Assignee
Johns Hopkins University
Asclepix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Asclepix Therapeutics Inc filed Critical Johns Hopkins University
Publication of CA3063140A1 publication Critical patent/CA3063140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3063140A 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide Abandoned CA3063140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502913P 2017-05-08 2017-05-08
US62/502,913 2017-05-08
PCT/US2018/031663 WO2018208829A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Publications (1)

Publication Number Publication Date
CA3063140A1 true CA3063140A1 (en) 2018-11-15

Family

ID=64104968

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063140A Abandoned CA3063140A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Country Status (8)

Country Link
US (1) US20200179285A1 (enExample)
EP (1) EP3621597A4 (enExample)
JP (1) JP2020518651A (enExample)
KR (1) KR20200003859A (enExample)
CN (1) CN111315364A (enExample)
AU (1) AU2018266690A1 (enExample)
CA (1) CA3063140A1 (enExample)
WO (1) WO2018208829A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ771201A (en) 2017-04-06 2025-01-31 Sustain Holdings Llc Collagen Peptide-Based Medicament Compositions And Devices And Methods Of Production And Use Thereof
EP3661536A4 (en) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR
KR20210146352A (ko) * 2019-03-26 2021-12-03 아스클리픽스 테라퓨틱스, 인크. 안구 질환 치료용 조성물 및 방법
PT3958889T (pt) 2019-04-22 2025-04-10 Sustain Holdings Llc Composições de péptidos miméticos de colagénio para o tratamento de uma doença ou perturbação ocular so segmento posterior que envolve a retina, os vasos sanguíneos da retina, os nervos retinianos ou o nervo ótico
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
DK3003343T3 (da) * 2013-06-07 2020-02-03 Univ Johns Hopkins Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme
JP2019535651A (ja) * 2016-10-04 2019-12-12 アスクレピクス セラピューティクス インコーポレイテッド Ｔｉｅ２シグナル伝達を活性化するための化合物及び方法

Also Published As

Publication number Publication date
WO2018208829A1 (en) 2018-11-15
EP3621597A1 (en) 2020-03-18
AU2018266690A1 (en) 2019-12-12
KR20200003859A (ko) 2020-01-10
US20200179285A1 (en) 2020-06-11
WO2018208829A8 (en) 2019-07-04
CN111315364A (zh) 2020-06-19
JP2020518651A (ja) 2020-06-25
EP3621597A4 (en) 2021-06-02

Similar Documents

Publication Publication Date Title
US20200179285A1 (en) Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
Lin et al. Stimulus‐responsive hydrogel for ophthalmic drug delivery
US9919032B2 (en) Method for administering a sustained release formulation
TWI459961B (zh) 長效人類生長激素共軛物之液態配方
US20140171370A1 (en) Formulations of active agents for sustained release
EP3424948B1 (en) Vascular endothelial growth factor targeting peptide-elastin fusion polypeptide and self-assembling nanostructure, which are for inhibiting angiogenesis
US20080085276A1 (en) Method of treating eye injury with local administration of a VEGF inhibitor
MX2007003789A (es) Suministro ocular de formulaciones polimericas para suministro.
KR20120130752A (ko) 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
Rana et al. Recent trends in drug delivery and emerging biomedical applications of gelatin for ophthalmic indications
JP7626362B2 (ja) 中枢神経系に神経保護ポリペプチドを送達する方法
CN110234336A (zh) 用于促性腺激素释放激素(GnRH)拮抗剂的长效释放的组合物和方法
ES2205481T3 (es) Microparticulas biodegradables para la liberacion sostenida de farmacos terapeuticos.
US20100081617A1 (en) Therapeutic agent for spinal cord injuries
Pescina et al. Therapeutics and carriers: the dual role of proteins in nanoparticles for ocular delivery
JP2020518651A5 (enExample)
EP2720684B1 (en) A sustained-release composition containing peptides as the active ingredient
Zidan et al. Formulation design in drug delivery
KR20180097517A (ko) 매우 안정된 인슐린 유사체의 중합체 용융물 내 캡슐화
CN105873570A (zh) 治疗性蛋白质的持续释放储槽式调配物和其用途
US20160333070A1 (en) Pro-angiogenic peptides and peptide conjugates
Dahiya et al. Ocular delivery of peptides and proteins
WO2025170943A1 (en) Methods and compositions to administer therapeutics to soft tissue surfaces
US20230054032A1 (en) Compositions and methods for treating ocular disease
WO2005040195A2 (en) Formulation of exendins

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231109